<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01588002</url>
  </required_header>
  <id_info>
    <org_study_id>NP28103</org_study_id>
    <nct_id>NCT01588002</nct_id>
  </id_info>
  <brief_title>A Study of Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir in Healthy Volunteers</brief_title>
  <official_title>A Study to Evaluate the Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir When Administered Together in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This phase 1, randomized, open-label, multiple-dose, 2-sequence, 2-period crossover study
      will evaluate potential drug-drug interaction between efavirenz and danoprevir with low-dose
      ritonavir in healthy volunteers. In Period 1. subjects will be randomized to receive multiple
      oral doses of either danoprevir with ritonavir or efavirenz for 14 days. In Period 2, all
      subjects will receive multiple oral doses of the combination danoprevir with ritonavir and
      efavirenz for 14 days. Anticipated time on study treatment is 28 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of efavirenz, danoprevir and ritonavir in coadministration: Cmax</measure>
    <time_frame>Pre-dose and up to 24 hours post-dose on Days 14 and 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of efavirenz, danoprevir and ritonavir in coadministration: Area under the concentration-time curve (AUC)</measure>
    <time_frame>Pre-dose and up to 24 hours post-dose on Days 14 and 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>approximately 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>A danoprevir+ritonavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B efavirenz</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>danoprevir</intervention_name>
    <description>multiple oral doses</description>
    <arm_group_label>A danoprevir+ritonavir</arm_group_label>
    <arm_group_label>C combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>efavirenz</intervention_name>
    <description>multiple oral doses</description>
    <arm_group_label>B efavirenz</arm_group_label>
    <arm_group_label>C combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir</intervention_name>
    <description>multiple oral doses</description>
    <arm_group_label>A danoprevir+ritonavir</arm_group_label>
    <arm_group_label>C combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female non-smoking subjects, 18 to 55 years of age

          -  Healthy status will be defined by absence of evidence of any active or chronic disease
             following a detailed medical and surgical history and a complete physical examination

          -  Medical history without major, recent or ongoing pathology

          -  Weight &gt;/= 50.0 kg

          -  Body mass index (BMI) 18.0 - 32.0 kg/m2

        Exclusion Criteria:

          -  Pregnant or lactating women or males with female partners who are pregnant or
             lactating

          -  History of any clinically significant medical condition which may impact the safety of
             the participant

          -  Positive results for drugs of abuse at screening or prior to admission to the clinical
             site during any study period

          -  Positive for hepatitis B, hepatitis C or HIV infection

          -  Current smokers or subjects who have discontinued smoking less than 6 months prior to
             first dose of study medication

          -  Use of hormonal contraceptives (e.g. birth control pill, patches, or injectable,
             implantable devices) within 30 days before the first dose of study medication

          -  Use of investigational drug or device within 30 days of the first dose of study
             medication (6 months for biologic therapies) or 5 half-lives of the investigational
             drug, whichever is longer

          -  History of drug-related allergic reaction

          -  History (within 3 months of screening) of alcohol consumption exceeding 2 standard
             drinks per day on average; alcohol consumption will be prohibited 72 hours prior to
             entry in the clinical site center and throughout the entire study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2012</study_first_submitted>
  <study_first_submitted_qc>April 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2012</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Lactams</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

